Like eager buyers queuing for the latest iPhone, urban Indians are chasing next-generation weight-loss injections regardless of price. Eli Lilly’s Mounjaro has dethroned long-time bestseller Augmentin, sparking an unprecedented market boom for GLP-1 drugs.
The iPhone effect in healthcare: How Mounjaro is rewriting the economics of India’s pharma market
Published ·
Keep reading
Related stories
